Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, Brent Vaughan, chief executive officer of Cognito Therapeutics, provided insight on the mechanism of action behind the company's gamma sensory stimulation as a potential therapy for patients with Alzheimer disease. He spoke on the positive phase 2 OVERTURE study presented at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference, including the notable takeaways from the trial and the safety profile observed. In addition, he commented on how this approach can be used with newer therapies and what the company is looking to achieve in a phase 3 trial.

Episode Breakdown:

1:10 – Overview of phase 2 OVERTURE study

4:45 – Mechanism of action of gamma sensory stimulation 

10:00 – Potential therapeutic crossover with emerging treatments

12:30 – Neurology News Minute

14:50 – Feasibility of the stimulation device

18:20– Future plans and planned phase 3 study

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.